OCUL
HealthcareOcular Therapeutix, Inc. · Biotechnology · $2B
What is Ocular Therapeutix, Inc.?
Ocular Therapeutix is a biopharmaceutical company focused exclusively on eye health, developing and commercializing therapies using its proprietary bioresorbable hydrogel technology. Founded in 2014 and headquartered in Bedford, Massachusetts, the company targets conditions ranging from post-surgical inflammation to retinal disease.
The company generates revenue primarily through its two commercialized products — ReSure Sealant and DEXTENZA — while simultaneously advancing a pipeline of sustained-release intravitreal and intracanalicular implants. Its hydrogel platform is designed to deliver drugs directly to ocular tissue over extended periods, reducing the need for frequent dosing. Ocular Therapeutix also pursues strategic collaborations, including a partnership with Regeneron Pharmaceuticals, to expand its reach into retinal disease treatment.
Ocular Therapeutix was founded in 2014 and is headquartered in Bedford, US.
- ReSure Sealant — prevents wound leaks after cataract surgery
- DEXTENZA — treats post-surgical ocular inflammation and allergic conjunctivitis
- OTX-TKI — intravitreal implant in Phase 1 for wet age-related macular degeneration
- OTX-TIC — intracameral implant in Phase 2 for open-angle glaucoma
- OTX-CSI and OTX-DED — inserts in clinical development for dry eye disease
Is OCUL a Good Stock to Buy?
UQS Score rates OCUL as Poor overall, placing it in the lowest tier of scored equities.
Among the five pillars, Risk is the one area that registers as Neutral — suggesting the company's risk profile is not as extreme as its other fundamentals might imply. This may reflect the stage-gated nature of its clinical pipeline and its existing commercial revenue base from DEXTENZA and ReSure Sealant.
Quality, Moat, and Growth all register as Weak, while Valuation is rated Elevated — a combination that signals the stock may be priced above what current fundamentals justify, with limited near-term catalysts to close that gap.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OCUL pay dividends?
No — Ocular Therapeutix, Inc. does not currently pay a dividend.
Ocular Therapeutix does not currently pay a dividend. This is typical for clinical-stage and early-commercial biopharmaceutical companies, which tend to reinvest available capital into research, clinical trials, and commercial infrastructure rather than returning cash to shareholders. Investors in OCUL are generally seeking pipeline-driven value appreciation rather than income.
When does OCUL report earnings?
Ocular Therapeutix reports earnings on a quarterly cadence, consistent with US-listed public companies.
Quarterly results for OCUL tend to reflect the interplay between DEXTENZA commercial uptake and ongoing pipeline spending. Investors typically watch for updates on clinical milestones alongside revenue trends, as pipeline progress can materially influence how the market interprets each quarter.
For the most recent quarter's results and guidance, visit Ocular Therapeutix's investor relations page directly.
OCUL Price History
-36.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Ocular Therapeutix, Inc.?
Based on Ocular Therapeutix, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
OCUL Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental trajectory for OCUL appears challenged. The company's path to improved scoring depends heavily on clinical trial outcomes — particularly for OTX-TKI and OTX-TIC — and on whether DEXTENZA can expand its commercial footprint meaningfully. The Regeneron collaboration adds optionality in retinal disease, but that upside remains contingent on development milestones that are not yet de-risked.
Growth drivers
- Continued commercial adoption of DEXTENZA across ophthalmic surgical centers
- Positive Phase 2 or Phase 1 readouts from OTX-TIC or OTX-TKI pipeline programs
- Expanded collaboration milestones with Regeneron in retinal disease
Key risks
- Clinical trial failures or delays across multiple pipeline candidates
- Elevated Valuation pillar rating leaves limited margin of safety if growth disappoints
- Competitive pressure in the ophthalmic drug delivery space from larger, better-capitalized peers
OCUL vs Peers
Ocular Therapeutix operates in a competitive specialty biopharmaceutical landscape alongside other clinical-stage and early-commercial companies.
Syndax focuses on hematology and oncology rather than ophthalmology, representing a different therapeutic area within the specialty biopharmaceutical space.
Aurinia is a commercial-stage biopharmaceutical company with a focus on autoimmune disease, offering a contrasting disease-area profile to OCUL's eye-health specialization.
Immunome is an oncology-focused biopharmaceutical company at an earlier commercial stage, sharing the clinical-risk profile common to small specialty biopharma peers.
Frequently Asked Questions
What does Ocular Therapeutix do?
Ocular Therapeutix develops and commercializes therapies for eye diseases using a proprietary bioresorbable hydrogel platform. Its marketed products address post-surgical inflammation and wound sealing after cataract surgery, while its pipeline targets conditions including wet age-related macular degeneration, glaucoma, and dry eye disease.
Does OCUL pay dividends?
No, Ocular Therapeutix does not pay a dividend. The company reinvests its resources into clinical development and commercial expansion, which is standard practice for biopharmaceutical companies at this stage of growth.
When does OCUL report earnings?
Ocular Therapeutix follows a standard quarterly reporting cadence. Specific dates are not covered by our data source — check the company's investor relations page for the current earnings calendar.
Is OCUL a good stock to buy?
UQS Score rates OCUL as Poor, reflecting Weak readings across Quality, Moat, and Growth pillars, combined with an Elevated Valuation. This profile suggests meaningful fundamental headwinds relative to its current market pricing. The full pillar breakdown is available to UQS Pro members.
Is OCUL overvalued?
The UQS Valuation pillar for OCUL is rated Elevated, indicating the stock may be priced above what current fundamentals support. For a company with Weak Quality and Growth scores, an Elevated Valuation leaves limited room for error if clinical or commercial results disappoint.
How does OCUL compare to its competitors?
OCUL operates in a niche within specialty biopharma, focused entirely on ophthalmology. Peers like Aurinia Pharmaceuticals and Syndax Pharmaceuticals address different therapeutic areas, making direct comparisons nuanced. UQS Pro members can view side-by-side pillar comparisons across these tickers.
What is OCUL's market cap bracket?
Ocular Therapeutix is classified as a mid-cap company. This places it above the micro- and small-cap tiers but below large-cap peers, reflecting its commercial-stage status and ongoing pipeline investment.
Who founded Ocular Therapeutix?
Ocular Therapeutix was founded in 2014. For detailed founding history and leadership background, the company's official about page and SEC filings are the most reliable sources.
Is OCUL a long-term quality investment?
As a long-term quality indicator, the UQS Score for OCUL currently sits in the Poor range. Sustained improvement would likely require meaningful clinical progress, stronger commercial execution, and a narrowing of the gap between Valuation and underlying fundamentals. Pro members can track pillar changes over time.
What is the main competitive advantage of Ocular Therapeutix?
Ocular Therapeutix's core differentiation lies in its bioresorbable hydrogel platform, which enables sustained drug delivery directly to ocular tissue. This technology underpins both its marketed products and its pipeline, and forms the basis of its collaboration with Regeneron Pharmaceuticals in retinal disease.
What sector does OCUL belong to?
OCUL is classified in the Healthcare sector, specifically within specialty biopharmaceuticals. Its focus on ophthalmic drug delivery distinguishes it from broader pharmaceutical and biotech peers. You can explore other [Healthcare sector stocks](/sector/healthcare) scored by UQS.
Is OCUL a growth stock or value stock?
Based on UQS pillar ratings, OCUL does not fit cleanly into either category in a favorable sense. Its Growth pillar is rated Weak and its Valuation pillar is Elevated, suggesting the market is pricing in future potential that current fundamentals have not yet validated.
Unlock Full OCUL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for OCUL
- ✓Access underlying financial metrics driving each pillar
- ✓Compare OCUL side-by-side with sector peers
- ✓Track pillar changes across quarterly reporting cycles
- ✓Screen for stronger-rated Healthcare alternatives
- ✓Get the complete analyst-style view in one dashboard
Pro Analysis
OCUL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 21.4 | 2.5 | 19.0 | 38.4 | 55.7 | 0.0 | +3.4 |
| May 8, 2026 | 18.0 | 0.0 | 19.0 | 38.4 | 36.9 | 0.0 | -2.6 |
| Apr 2, 2026 | 20.6 | 2.5 | 19.0 | 38.4 | 50.4 | 0.0 | — |
OCUL — Pillar Breakdown
Quality
— 2.5/100 (25%)Ocular Therapeutix, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 38.4/100 (20%)Ocular Therapeutix, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 55.7/100 (15%)Ocular Therapeutix, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Ocular Therapeutix, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)Ocular Therapeutix, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OCUL.
Score Composition
Financial Data
More Stock Analysis
How is the OCUL UQS Score Calculated?
The UQS (Unified Quality Score) for Ocular Therapeutix, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ocular Therapeutix, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ocular Therapeutix, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.